Abstract
Vildagliptin a selective inhibitor of dipeptidyl peptidase-4, and prevents the rapid degradation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Vildagliptin has been evaluated in > 4800 patients in nine Phase III studies in the range of 24 - 52 weeks in duration: four placebo-or active-controlled monotherapy trials that enrolled drug-naive patients, four add-on studies in which vildagliptin was addedd to a stable regimen of either metformin, a sulfonylurea, a thiazolidinedione or insulin, and a study in which an initial combination, of vildagliptin plus, pioglitazone in drug-naive patients was evaluated. Across studies, vildagliptin was effective in reducing HbA1c, had a low risk of hypoglycemia and was weight-neutral and well tolerated.
Original language | English (US) |
---|---|
Pages (from-to) | 105-113 |
Number of pages | 9 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
Keywords
- DPP-4
- Glycemic control
- HbA
- Type 2 diabetes
- Vildagliptin
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)